Skip to main content
Livermore
Livermore
ZHEN

Regulus Therapeutics Inc.

RGLSDelisted Jun 25, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001505512

Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.

Holders of 5% or more of RGLS

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Regulus Therapeutics Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Regulus Therapeutics Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

38 Schedule 13D and 13G filings on Regulus Therapeutics Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on RGLS
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20255:23 PM ETPoint72 Asset Management, L.P.and 2 others13G/A0.30%241.2K shares−5.60 ppfrom 5.90%Below 5%Jun 30, 2025SEC
Aug 14, 20258:50 AM ETDeep Track Capital, LPand 2 others13G/A0.00%0 shares–Below 5%Jun 30, 2025SEC
May 15, 20258:35 AM ETVivo Opportunity Fund Holdings, L.P.and 1 other13G/A3.90%2.70M shares–Below 5%Mar 31, 2025SEC
Apr 8, 20254:30 PM ETPoint72 Asset Management, L.P.and 2 others13G5.90%3.92M shares–Apr 1, 2025SEC
Nov 14, 2024DAFNA Capital Management LLC13G/AOld format–––SEC
Nov 14, 2024Ra Capital Management, L.P.13G/AOld format–––SEC
Nov 14, 2024Biotechnology Value Fund L P13G/AOld format–––SEC
Nov 12, 2024Vanguard Group Inc13G/AOld format–––SEC
Nov 8, 2024BlackRock, Inc.13GOld format–––SEC
Nov 4, 2024Vanguard Group Inc13G/AOld format–––SEC
Oct 24, 2024BlackRock, Inc.13GOld format–New–SEC
Oct 11, 2024Octagon Capital Advisors LP13GOld format–New–SEC
Apr 10, 2024FMR LLC13G/AOld format–––SEC
Mar 25, 2024Ra Capital Management, L.P.13GOld format–New–SEC
Mar 22, 2024Deep Track Capital, LP13GOld format–New–SEC
Mar 20, 2024Vivo Opportunity Fund Holdings, L.P.13GOld format–New–SEC
Mar 18, 2024Growth Equity Opportunities V, LLC13D/AOld format–––SEC
Feb 14, 2024DAFNA Capital Management LLC13GOld format–New–SEC
Feb 9, 2024FMR LLC13G/AOld format–––SEC
Feb 6, 2024Victory Capital Management Inc13G/AOld format–––SEC
Jan 18, 202410:25 AM ETFederated Hermes, Inc.13G/AOld format–––SEC
May 12, 2023Growth Equity Opportunities V, LLC13D/AOld format–––SEC
May 10, 20239:58 AM ETFederated Hermes, Inc.13G/AOld format–––SEC
Feb 1, 202311:43 AM ETFederated Hermes, Inc.13G/AOld format–––SEC
Jan 31, 2023Victory Capital Management Inc13G/AOld format–––SEC
Oct 11, 2022FMR LLC13GOld format–New–SEC
May 16, 20222:35 PM ETFederated Hermes, Inc.13GOld format–New–SEC
Feb 14, 2022Altium Capital Management LP13G/AOld format–––SEC
Feb 14, 2022EcoR1 Capital, LLC13G/AOld format–––SEC
Feb 14, 2022Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 14, 2022Point72 Asset Management, L.P.13G/AOld format–––SEC
Feb 2, 2022Victory Capital Management Inc13G/AOld format–––SEC
Jan 4, 2022Victory Capital Management Inc13G/AOld format–––SEC
Dec 9, 2021Growth Equity Opportunities V, LLC13D/AOld format–––SEC
Mar 8, 2021Victory Capital Management Inc13GOld format–New–SEC
Feb 16, 2021Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 12, 2021Altium Capital Management LP13G/AOld format–––SEC
Feb 12, 2021EcoR1 Capital, LLC13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Regulus Therapeutics Inc. shares.

No Form 144 notices for Regulus Therapeutics Inc. are on file.